ARTICLE | Discovery & Translation
Omics-based target identification in UK Biobank and COVID-19 cohorts
Plus: technologies from Harvard, Texas A&M, Disney lab and more
October 29, 2021 9:59 PM UTC
Updated on Nov 1, 2021 at 8:22 PM UTC
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and HiberCell Inc. separately unveiled results from large-scale multi-omics analyses identifying genetic modifiers of disease.
Making good on its commitment to the UK Biobank, Regeneron Genetics Center reported in Nature findings from its analysis of exomes from 454,787 participants in the biobank. ...